Quantcast

Ganeden Biotech Announces UK-based Leatherhead Food Research As Its Approved European Testing Lab

September 18, 2013

As its expansion into the European market increases, Ganeden Biotech takes steps to offer assistance and convenience for its partners.

Cleveland, OH (PRWEB) September 18, 2013

Ganeden Biotech, a recognized world leader in the manufacturing and marketing of probiotics, announces that to further support its European partners in the product formulation process Leatherhead Food Research has been validated to test products containing GanedenBC30. The endorsement will ensure that European customers receive quality and accurate product testing, while eliminating excessive logistical delays and customs concerns that can arise when their products are tested in the United States.

“We have seen tremendous growth within the European market, and it is increasingly important to have a high quality, reputable lab that we are able to recommend to our partners,” said Michael Bush, Ganeden Biotech’s Vice President. “Due to existing import agreements within the European Union, validating Leatherhead will eliminate the difficulties that our partners experience when shipping their product to our Cleveland, OH facility for testing”.

Leatherhead’s applied research capabilities and unique offerings have delivered added value to a global client base for more than ninety years. Based just outside London, UK, this independent organization offers practical advice, tailored consultancy, research and business-oriented support, closely aligned to customer’s strategic and everyday demands. Leatherhead compliments Ganeden’s portfolio of labs and offers significant benefits to its European partners.

About Ganeden Biotech:

Ganeden Biotech is at the forefront of probiotic research and product development with an extensive library of published studies and more than 100 patents for probiotic technologies in the food, beverage, animal health, and now personal care ingredients markets. Ganeden is best known for GanedenBC30® (Bacillus coagulans GBI-30, 6086), its patented, FDA GRAS, highly stable probiotic ingredient. Ganeden's newest ingredient, Bonicel, is the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. For more information about Ganeden Biotech and licensing opportunities, visit http://www.GanedenBiotech.com.

About Leatherhead Food Research:

Founded in 1919, Leatherhead Food Research, based near London, UK, is a leading independent organization delivering integrated scientific, technical, market and regulatory research and consultancy solutions to the global food, beverage and related industries.

Leatherhead’s applied research capabilities and unique offering have delivered added value to a global client base for over ninety years. Leatherhead offers practical advice, tailored consultancy, research and business-oriented support, closely aligned to customer’s strategic and everyday demands. The company’s services, built around five key platforms each representing a core area of expertise, are supported by a wealth of related and up-to-date information resources. The platforms are: Food Innovation, Global Food Regulations, Sensory, Consumer & Market Insight, Food Safety and Nutrition. To learn more, visit http://www.LeatherheadFood.com

About GanedenBC30:

Ganeden Biotech’s probiotic, GanedenBC30® (Bacillus coagulans GBI-30, 6086), is a patented, organism that can be found in more than 80 leading food, beverage and companion animal products throughout the world. Unlike most other probiotic strains used in food and beverages, GanedenBC30 is highly stable and can remain viable through processing, shelf life and the low pH of stomach acid. The efficacy of GanedenBC30 is backed by 17 published studies. GanedenBC30 has an exceptional safety record and FDA GRAS status from the United States Food and Drug Administration. For more information, please visit http://www.GanedenBC30.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11131524.htm


Source: prweb



comments powered by Disqus